Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.14
-0.06 (-1.15%)
At close: Aug 7, 2025, 4:00 PM
5.13
-0.01 (-0.19%)
After-hours: Aug 7, 2025, 7:45 PM EDT

Company Description

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.
Ardelyx logo
CountryUnited States
Founded2007
IPO DateJun 19, 2014
IndustryBiotechnology
SectorHealthcare
Employees395
CEOMichael Raab

Contact Details

Address:
400 Fifth Avenue, Suite 210
Waltham, Massachusetts 02451
United States
Phone510 745 1700
Websiteardelyx.com

Stock Details

Ticker SymbolARDX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001437402
CUSIP Number039697107
ISIN NumberUS0396971071
SIC Code2834

Key Executives

NamePosition
Michael G. RaabPresident, Chief Executive Officer and Director
Justin A. Renz CPA, MBAChief Financial and Operations Officer
Elizabeth A. Grammer Esq.Chief Legal and Administrative Officer and Secretary
Dr. Laura A. Williams M.D., M.P.H.Chief Patient Officer
Mike KelliherChief Business Officer
Joseph ReillySenior Vice President of Finance and Principal Accounting Officer
Caitlin LowieVice President of Corporate Communications and Investor Relations
James P. BradyChief Human Resources Officer
David P. Rosenbaum Ph.D.Head of Drug Discovery and Early Development
Eric Duane FosterChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Aug 4, 202510-QQuarterly Report
Aug 4, 20258-KCurrent Report
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 3, 20258-KCurrent Report
Jun 25, 2025SCHEDULE 13GFiling
Jun 18, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 2, 2025144Filing
May 1, 202510-QQuarterly Report
May 1, 20258-KCurrent Report